The Worldwide Economic Impact of Neurogenic Bladder

被引：12

作者：

Flack C. ^{[1
]}

Powell C.R. ^{[1
]}

机构：

[1] Department of Urology, Indiana University School of Medicine, 535 Barnhill Dr., Suite 420, Indianapolis, 46202, IN

来源：

Current Bladder Dysfunction Reports | 2015年 / 10卷 / 4期

关键词：

Costs and cost analysis; Health expenditures; Incontinence pads; Intermittent urethral catheterization; Urinary bladder—neurogenic; Urinary bladder—overactive; Urinary incontinence; Urinary retention;

D O I：

10.1007/s11884-015-0323-6

中图分类号：

学科分类号：

摘要：

Costs of neurogenic bladder vary widely and depend on a number of factors including severity of disease, symptomatology, patient insurance, and devices required. Recognition of how each treatment strategy will impact the patient financially could help guide selection of treatment as well as improve compliance with the chosen regimen. We have attempted to provide an overview of long-term cost considerations for the neurogenic bladder patient. Armed with this information, the practitioner can better help the patient select a bladder care regimen that balances the desire to both minimize symptoms now and preserve urinary tract integrity for the future, yet still remain cost-effective. © 2015, Springer Science+Business Media New York.

引用

页码：350 / 354

页数：4

共 27 条

[1]

Manack A., Motsko S.P., Haag-Molkenteller C., Dmochowski R.R., Goehring E.L., Nguyen-Khoa B.A., Et al., Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database, Neurourol Urodyn, 30, 3, pp. 395-401, (2011)

[2]

Ginsburg D., The epidemiology and pathophysiology of neurogenic bladder, Am J Manage Care, 19, pp. S191-S196, (2013)

[3]

Stohrer M., Blok B., Castro-Diaz D., Chartier-Kastler E., Del Popolo G., Kramer G., Et al., EAU guidelines on neurogenic lower urinary tract dysfunction, Eur Urol, 56, 1, pp. 81-88, (2009)

[4]

Muller N., Savings on surgical devices pale in comparison to benefits of advanced procedures, Mod Healthc, 36, 32, (2006)

[5]

Gormley E.A., Lightner D.J., Burgio K.L., Chai T.C., Clemens J.Q., Culkin D.J., Et al., Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline, J Urol, 188, pp. 2455-2463, (2012)

[6]

McClurg D., Ashe R.G., Lowe-Strong A.S., Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis—a double blind, placebo controlled, randomised clinical trial, Neurourol Urodyn, 27, 3, pp. 231-237, (2008)

[7]

Newman D.K., Willson M.M., Review of intermittent catheterization and current best practices, Urol Nurs, 31, 1, pp. 12-28, (2011)

[8]

Prieto J., Murphy C.L., Moore K.N., Fader M., Intermittent catheterisation for long-term bladder management, Cochrane Database Syst Rev, 9, 9, (2014)

[9]

Wyndaele J., Complications of intermittent catheterization: their prevention and treatment, Spinal Cord, 40, 10, pp. 536-541, (2002)

[10]

Prieto J.A., Murphy C., Moore K.N., Fader MJ, (2015)

← 1 2 3 →